Introduction: Osimertinib showed great clinical efficacy for activated-EGFR NCLC patient treatment. The aim of this work was to test the efficacy of a complete EGFR-inhibition by osimertinib plus the monoclonal antibody cetuximab or the MEK1/2-inhibitor selumetinib in EGFR-mutated NCLC in vivo models.
Introduction
Non-small cell lung cancer (NCLC) is one of the leading causes of cancer-related death worldwide and oncological medical treatment for metastatic diseases is still only palliative.
1,2 Molecular characterization defined "selected" NCLC patients, harboring epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocation, which account together for the approximately 15% of lung adenocarcinomas in the Caucasian population and are positive predictive and prognostic biomarkers. 3 In particular, 90% of activating EGFR mutations are exon 19 deletion (E746-A759del) or exon 21 L858R point mutations; other uncommon mutations are located in exons 18-21 of the EGFR gene. 3, 4 Therapeutic options for EGFR-mutated NCLC patients include three generations of EGFR-tyrosine kinase inhibitors (EGFR-TKIs): first-generation reversible EGFRTKIs, gefitinib and erlotinib, second-generation irreversible EGFR-TKIs such as afatinib, and third-generation irreversible EGFR-TKIs such as osimertinib, designed to overcome T790M-resistance sparing wild-type EGFR. 5 EGFR-exon 20-T790M-mutation appears at resistance to first-line EGFR-TKI therapy in 50% of cases, probably as selection of a pre-existing clone. It resulted in substitution of threonine to methionine at the "gatekeeper" amino acid 790 and negatively influenced the sensitivity to firstgeneration EGFR-TKIs through a major adenosine triphosphate affinity and steric effect. 6, 7 Other mechanisms of resistance include activation of HER2, 8 MET, 9 PIK3CA, 10 BRAF, 11 NF1, 12 FGFR, 13 AXL, 14 and hedgehog 15, 16 or histologic changes to small cell lung cancer (SCLC) or epithelial-to-mesenchymal transition. 17 Various strategies have been proposed to overcome resistance to first-generation EGFR-TKIs, including the use of irreversible EGFR-TKIs. 7, 17 Afatinib is the best known pan-HER irreversible EGFR-TKI. In preclinical studies it has been shown able to overcome firstgeneration EGFR-TKI resistance and its activity seems to be potentiated by combination with cetuximab also in T790M-positive tumors 18, 19 ; however, afatinib plus cetuximab combination in clinic was affected by important side effects. 19 Osimertinib is a potent irreversible EGFR-TKI targeting both EGFR-sensitizing and T790-mutated cells; data from the AURA3 phase III trial confirmed the superiority of osimertinib versus chemotherapy in EGFRmutated NCLC patients with acquired resistance to first-generation EGFR-TKIs due to T790M. 20 Preclinical and recent clinical data from the FLAURA trial showed that osimertinib has a strong efficacy also in EGFR-TKInaïve NCLC, independently from T790M. 21, 22 Some data are already available on resistance to osimertinib, 23, 24 including the activation of RAS. 23 Recently, our group showed that EGFR-mutated NCLC maintains EGFR dependency after the onset of resistance to EGFR-TKIs and can benefit from continuous treatment with a sequence of EGFR inhibitors: first-generation EGFR-TKIs, second-generation EGFR-TKI afatinib plus cetuximab, and third-generation EGFR-TKI osimertinib, independently from mechanisms of resistance. 16 Considering the fundamental EGFR dependency and the role of the RAS/MAPK pathway as escaping mechanism to EGFR inhibition, 16, 23 we designed an investigational strategy of treatment aiming to a more potent inhibition of EGFR signaling in EGFR-mutated NCLC models (both T790M-positive and -negative) by reinforcing the effect on the receptor with the monoclonal antibody cetuximab, or on downstream pathways by inhibiting MAPK with the selective MEK1/2-inhibitor selumetinib in addition to osimertinib in second-line treatment in osimertinibresistant tumors and in first-line treatment. In particular, we investigated the best therapeutic option among these combinational strategies and we explored the mechanisms of acquired resistance to these treatments.
Materials and Methods

Cell Lines and Drugs
The human NCLC HCC827, PC9, and H1975 cell lines were provided by American Type Culture Collection (ATCC, Manassas, Virginia) and maintained in RPMI-1640 (Sigma-Aldrich) medium supplemented with 10% fetal bovine serum (FBS) (Life Technologies, Gaithersburg, Maryland) in a humidified atmosphere with 5% CO 2 . The identity of all cell lines was confirmed by STR profiling (Promega) on an ad hoc basis before performing experiments. PC9T790M cell clone was generated by exposing the PC9 parental cell line to increasing concentration of gefitinib. 25 This cell clone is cultured in the presence of gefitinib 1 mM to maintain a selection pressure during in vitro propagation.
Gefitinib, afatinib, LDE-225 (NVP-LDE225, sonidegib), selumetinib (AZD6244), vismodegib, and cetuximab were purchased from Selleck Chemicals (Selleckchem). Osimertinib was generously provided by AstraZeneca.
Cell Proliferation Assay
Cancer cells were seeded in 96-multiwell plates and were treated with different doses of indicated drugs for 72 hours. Cell proliferation was evaluated by the 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay, as previously described. 16 Concentration that inhibits 50% of cell growth (IC 50 ) was determined by interpolation from the dose-response curves. Results represent the median of three separate experiments, each performed in triplicate.
Migration and Invasion Assay
Cell migration was assessed using a commercially available chemotaxis assay. 16 The in vitro invasive ability of cells was measured by using Transwell chambers (Corning Life Sciences, Tewksbury, MA) according to the manufacturer's protocol. Assays were performed in triplicate.
Growth in Soft Agar
Cells (10 4 cells/well) were suspended in 0.5 mL 0.3% Noble agar (Sigma-Aldrich) dissolved in complete culture medium. This suspension was layered over 0.5 mL 0.8% agar-medium base layer in a 12-multiwell plate for indicated treatments. When tumor cell colonies were at least 80 mm they were counted by using a dissection microscope. Assays were performed in triplicate.
Tumor Xenografts in Nude Mice
Four-to-six-week old female balb/c athymic (nuþ/nuþ) mice were purchased from Charles River Laboratories. The research protocol was approved and mice were maintained in accordance with the Institutional Guidelines of the University of Naples "Luigi Vanvitelli" Animal Care and Use Committee. Mice were acclimatized for 1 week before being injected with cancer cells and injected subcutaneously with 10 7 HCC827, H1975, or PC9T790M cells that had been diluted in 200 mL of Matrigel (Corning Life Sciences), 1:1 in culture medium. When tumors reached a mean volume of 200 mm 3 , mice were randomized into different treatment groups (20 mice/group): osimertinib alone (increasing doses each week from 6.25 to 12.5 to 25 mg/kg orally, 5 days a week) or plus selumetinib (25 mg/ kg orally, 5 days a week) or cetuximab (1 mg twice a week, intraperitoneally) until progression (defined as a >30% increment of tumor volume from baseline) in first-line therapy. At time of progression, mice in the osimertinibalone group were randomized 1/1 to osimertinib plus selumetinib or cetuximab as second-line therapy and treated until progression. Tumor volume was measured using the formula p/6 Â larger diameter Â (smaller diameter) 2 . Median volumes are indicated in Supplemental Table 1 . Tumor volume was monitored on alternate days. For monitoring tumor responses to therapy, we measured volumetric changes and used an arbitrary classification method modified from clinical research methods: complete response (CR) was defined as no clinical evidence of tumor, confirmed when mice were sacrificed; partial response (PR) as a decrease of at least 30% in tumor volume with respect to the baseline tumor volume; progression disease (PD) as an increase of at least 30% in the tumor volume with respect to the baseline tumor volume; responses that were neither sufficient to categorize PR or PD were considered stable disease. Experiment end-time was fixed to 52 weeks. The toxicities were assessed by measuring body weight every other day, monitoring the amount of feed intake to estimate loss of appetite by control of stool characteristics to assess the appearance of diarrhea, and by clinical evaluation by the veterinarian for ocular toxicity.
At the time of progression to osimertinib first-line treatment, fine needle aspiration cytology with a 23G needle was performed for next-generation sequencing (NGS) analysis before the start of second-line treatment. 26 For all mice experiencing progression to combined treatment during first-or second-line, tumor samples were collected from xenografts by tumor dissection for NGS, protein extraction for Western blot analysis, establishment of in vitro primary cell cultures for in vitro proliferation, and metastatic assays, as described below.
Multiple Gene Mutation Analysis by NGS
DNA was extracted using the QIAamp DNA Mini Kit (Qiagen) according to the manufacturer's instructions and analyzed with the Ion AmpliSeq Library 96LV Kit 2.0 and the Hot Spot Cancer Panel (Life Technologies), 27 including genes indicated in Supplementary Table 2 .
Luciferase Assay
Luciferase assay was performed using the DualLuciferase Assay system (Promega) using GLI-Lucreporter-plasmid as previously indicated. 28 
Protein Expression Analysis
Tumor samples harvested from mice were cut into 20-mm 3 pieces and stored in RNA later until protein extraction. Protein lysates were obtained by homogenization in RIPA lysis buffer (Sigma-Aldrich) buffer and clarification by centrifugation at 14,000 rpm for 15 min a 4 C. Protein samples were normalized by Bradford assay (Bio-Rad), subjected to Western blot, and immunocomplexes were detected using the ChemiDoc (Bio-Rad) after hybridation with primary antibodies against SMO, Gli1, p-MAPK, and MAPK (Cell Signaling Technology) and antia-tubulin (Sigma Chemical). Each experiment was performed in triplicate.
Establishment of In Vitro Primary Cell Cultures
Tumor tissues were minced with scissors in a sterile manner. Tumor cells were dissociated by digestion buffer made by RPMI medium plus PenicillinStreptomycin and Amphotericin B, 1XCollagenase and 1XHyaluronidase enzyme (Sigma-Aldrich), in 37 C shaker overnight. Pellets were then resuspended in RPMI-medium supplemented with EGF (Sigma-Aldrich). A cell culture was considered established if it could be carried through at least five in vitro passages.
Statistical Analysis
The Student t test was used to evaluate the statistical significance of differences between treatment effects. Progression-free survival (PFS) curves were plotted using the Kaplan-Meier method and compared using the Log-rank test. All the tests were two-sided, with p value of less than 0.05 considered statistically significant. All analyses were performed using the SPSS package (version 21.0 for Windows, SPSS, IBM, Armonk, NY).
Results
Effects of Osimertinib In Vitro on EGFR-Mutated NCLC Cell Lines
Among our panel of NCLC cell lines, we selected HCC827, harboring EGFR E746-A750 deletion in exon 19 mutation, and two EGFR T790M-positive models, H1975 (EGFR L858R, T790M) and PC9T790M (EGFR exon 19-E746-A750-deletion, T790M) cells, as representative of a hypothetic clinical scenario. In particular, we consider the model HCC827 as representative of patients harboring the most common activating mutations of EGFR (i.e., E746-A759del and L858R) known to be very sensitive to first-generation EGFR-TKIs, and H1975 and PC9T790M as models for intrinsic and acquired resistance to first-generation EGFR-TKIs, respectively. Doseresponse treatment curves of H1975 and PC9T90M cells with gefitinib, afatinib and osimertinib showed IC 50 values for afatinib of 1 mM in both cell lines and for osimertinib of 0.1 mM in H1975 and 0.01 mM in PC9T790M by MTT assay (Supplemental Figs 1A and 1B) and confirmed resistance to gefitinib with IC 50 >5 mM; instead, HCC827 cells were very sensitive to all three EGFR-TKIs (IC 50 values between 0.01 and 0.05 mM) (Supplemental Fig 1C) . H1975 and PC9T790M cells exhibited in vitro significant invasive, migratory, and anchorage-independent colony growth abilities that were strongly inhibited by osimertinib to 50% and 25% (Supplemental Fig 1D) , whereas HCC827 had no significant migratory and invasive properties according to correction in vitro (data not shown).
Efficacy of Osimertinib in First-Line Treatment in EGFR-Mutated NCLC Xenografts
HCC827, H1975, and PC9T790M NCLC cells were injected subcutaneously into the dorsal flank of nude mice and, after 2 weeks, when tumor size was approximately 200 mm 3 , 20 mice per group were treated respectively with osimertinib. Osimertinib treatment showed strong antitumoral efficacy in terms of growth inhibition in all models. In particular, osimertinib treatment reached a response rate (RR) at 4 weeks of 100% in HCC827, H1975, and PC9T790M xenografts, 
Effects of the Addition of Selumetinib or Cetuximab in Second-Line Therapy of Osimertinib-Resistant NCLC Xenografts
Eight HCC827, 12 H1975, and 10 PC9T790M osimertinib-resistant xenografts were randomized into two groups (4 mice per group for HCC827 xenografts, 6 mice per group for H1975 xenografts, and 5 mice per group for PC9T790M xenografts) to receive, in addition to ongoing osimertinib treatment, selumetinib or cetuximab (Supplemental Fig. 2) . In all groups, combinations induced significant tumor shrinkage in all tumors, with 100% RR after 4 weeks (Figs. 1C, 2C , and 3C). After 14 weeks, RR was 75% in HCC827 osimertinib-resistant xenografts treated with osimertinib plus selumetinib (1 of 4 had PD and 3 of 4 had CR) and 50% in the osimertinib plus cetuximab arm (2 of 4 had PD and 2 of 4 had CR) (Figs. 1C, and 1D ). In the H1975 osimertinib resistant-group, RR was 66.6% in both arms (2 of 6 had PD and 4 of 6 had CR) (Figs. 2C and 2D). In PC9T790M xenografts, RR was 60% in the osimertinib-plus-selumetinib arm (2 of 5 had PD and 3 of 5 had CR) and 80% in the osimertinib-pluscetuximab arm (1 of 5 had PD and 4 of 5 had CR) (Figs. 3C and 3D ). All responses lasted for the fixed observation time of 52 weeks from the start of first-line therapy. Similar to first-line, treatments were continued until the development of PD. Median DoT was not reached in any of the xenograft groups (Figs. 1D, 2D , and 3D). Both combination treatments were well tolerated with no significant weight loss or other toxicities (data not shown).
Antitumor Efficacy of First-Line Treatment With Osimertinib Plus Selumetinib or Cetuximab in EGFR-Mutated NCLC Xenografts
Similar to previous groups of treatments, HCC827, H1975, and PC9T790M NCLC xenografted mice (20/group) were randomized to osimertinib plus selumetinib or cetuximab (Supplemental Fig. 2, Fig. 4 ).
All combinations achieved 100% RR in the three models (Fig. 4) at 3 weeks of treatment, with all mice maintaining PR until week 8. At week 30, in H1975 xenografts in the osimertinib-plus-selumetinib arm, RR was 80% (8 of 10 had CR and 2 of 10 had PD), whereas in the osimertinib-plus-cetuximab arm, RR was 90% (8 of 10 had CR, 1 of 10 had PR, and 1of 10 had PD) (Fig. 4A) . In PC9T790M and HCC827 xenografts, at the same treatment time point, we detected in both arms an RR of 90% with only 1 of 10 having PD in each arm of therapy (Figs. 4B and 4C ). Thus, a majority of mice showed CR as the best response to first-line combination treatments, exactly 86.67% mice with osimertinib plus selumetinib (26 of 30) and 90% with osimertinib plus cetuximab (27 of 30), and maintained these response for all the duration of the experiment (fixed to 52 weeks). Until the moment of programmed sacrifice of mice, no significant toxicities were recorded (data not shown).
Analysis of PFS in Sequential Versus First-Line Treatments With Osimertinib Plus Selumetinib or Cetuximab in EGFR-Mutated NCLC Xenografts
We compared the results of the two designed strategies of treatment through a statistical analysis according to the Kaplan-Meier method for PFS. As indicated in Figure 5 , first-line treatment with combinations showed a statistically significant superiority in terms of PFS versus osimertinib in the three groups. Median PFS (mPFS) in the osimertinib arm was 17 weeks (95% confidence interval: 14.01-19.9, p ¼ 0.001) in H1975-, 18 weeks (95% confidence interval: not reached, p ¼ 0.003) in PC9T790M-and was not reached in HCC827-xenografts. In the combination arm mPFS was not reached in all three groups. Second-line treatments with osimertinib plus selumetinib or cetuximab in osimertinib-resistant xenografts showed no statistically significant difference (data not shown), with mPFS not reached in either group. The mPFS of first-line treatment with osimertinib plus second-line treatment with combination treatments calculated in mice experiencing PD to second-line therapy was of 29 weeks in HCC827, 27.5 weeks in H1975, and 28 weeks in PC9T790M xenografts, respectively.
Analysis of Molecular Mechanisms of Resistance to First-Line Osimertinib and to Combination Treatments With Cetuximab or Selumetinib in First-or in Second-Line Treatment in EGFRMutated NCLC Xenografts
NGS was performed on fine needle aspiration cytology samples from osimertinib-resistant xenografts at the time of clinical PD1, and on tumor samples collected from xenografts treated with combinations of osimertinib plus selumetinib/cetuximab, after second-or first-line therapy.
As control, we used HCC827, H1975, and PC9T790M cells that had not undergone any type of treatment. No new mutations were found in derived resistant tumors, as compared to parenteral cell line, only a significant reduction in allelic frequency of known EGFR mutations was detected (Supplementary Table 2 ). These data confirmed that a complete EGFR pathway of pharmacological inhibition exerted a strong negative selective pressure on EGFR-positive subclones and favor the development of EGFR-independent subclones, indicating the need to study alternative pathways as a mechanism of resistance to EGFR.
Considering our previous data on the role of hedgehog in multiple models of EGFR inhibition, we investigated protein levels of the two specific hedgehog proteins, SMO and Gli1, on extracts from tumor samples derived from H1975 8* osimertinib þ selumetinib and PC9T790M 2* osimertinib plus selumetinib-resistant tumors by Western blot analysis and we found that they are increased as compared to HCC827 and PC9 cells, known as a negative control for hedgehog pathway activation from our previous data 15 and to their respective parental cell lines (H1975 and PC9T790M cells) (Fig. 6A) . p-MAPK levels were similarly high in resistant tumors, with the total MAPK protein level not significantly variable among all samples (Fig. 6A) . MET, AXL, IGF-1-R, and HER2 protein levels were not significantly increased in these two cell models (data not shown).
To determine whether there is functional activation of the hedgehog pathway in the two cell cultures established in vitro from first-line osimertinib-plusselumetinib-resistant tumors (H1975 8* and PC9T790M 2*), we used a Gli-luciferase assay (Fig. 6B) . 15 Luciferase assay revealed an increased Gli-responsive promoter activity to 6-and 9-fold increase in H1975 cells and H1975 8* osimertinib plus selumetinib-R, respectively, and a 4-fold increase in PC9T790M cells and 8-fold increase in PC9T790M 2* osimertinib plus selumetinib-R, comparing to medium levels between PC9 and HCC827 cells (Fig. 6B) . Hedgehog activation is one of the mechanisms of resistance in the context of epithelial-tomesenchymal transition in EGFR-resistant NCLC as we previously showed in T790M-negative models 15 ; thus, we investigated whether hedgehog inhibition, by the use of a selective SMO inhibitor, sonidegib, or vismodegib (Supplemental Fig. 3 ), can affect cell proliferation and migratory and invasive properties (Figs. 6C and 6D) . MTT assays were performed in the presence of sonidegib (0.1 to 0.5 1 mM) as single agent or in combination with selumetinib and osimertinib (Fig. 6C ). Cells were completely refractory to selumetinib and osimertinib as single agent and combined treatment, confirming resistance during in vivo experiment (data not shown). Triple combination of sonidegib with osimertinib and selumetinib affected significantly the viability and the migratory and invasive properties of cells to 20%, reverting EGFR sensitivity (Figs. 6C and 6D) . Similar results were obtained with vismodegib (data not shown).
Discussion
Preclinical and clinical evidence suggested that osimertinib, the most well-known among third-generation EGFR-TKIs, can overcome resistance to first-generation EGFR-TKIs and is the best EGFR-TKI for EGFR-mutated NCLC due to its affinity for sensitizing and T790M mutation and ability to spare EGFR wild-type receptor, avoiding high toxicity rates. 21, 22 In particular, the AURA3 trial showed that osimertinib has significantly greater efficacy in terms of RR and PFS than platinum-based chemotherapy in EGFR-mutated NCLC patients (including those with poor prognosis due to the development of brain metastases) after progression to A B C first-line EGFR-TKI therapy and onset of T790M. 20 Recently, updated results of a pre-planned pooled analysis for overall survival (OS) of phase II AURA studies showed a median OS of 26.8 months in pretreated EGFRmutated T790M-positive NCLC. 29 Moreover, in the FLAURA trial, 22 the first trial comparing in first-line osimertinib versus other available anti-EGFR-targeted drugs, the mPFS was 18.9 months in the osimertinib group and 10.2 months in the standard EGFR-TKI group, with a median duration of exposure to treatment of 16.2 months versus 11.5 months, respectively; data for OS are still immature. 22 The known mechanisms of resistance to osimertinib include the onset of a secondary mutation in the binding site of EGFR, C797S mutations, and activation of alternative pathways such as HER2, MET, and RAS; they are similar to mechanisms fully demonstrated for resistance to first-generation EGFR-TKIs, thus suggesting that EGFR-resistant cells activate common ways of escape to EGFR inhibition by overactivation of other receptors or by converging on downstream signaling, such as MAPK. 23, 24 Tricker et al. 30 showed in EGFRmutated NCLC cells that MAPK is reactivated after treatment with WZ4002, another irreversible EGFR-TKI with activity against T790M clones, and that concomitant treatment with WZ4002 and an MEKinhibitor trametinib delayed resistance to WZ4002 preventing MAPK reactivation independent of the onset of T790M in vitro. Osimertinib plus selumetinib is currently being investigated in a phase IB trial in EGFRmutated NCLC patients who progressed to EGFR-TKI therapy (NCT02143466).
We compared osimertinib plus cetuximab or selumetinib to determine the best therapy to delay or revert resistance to osimertinib, the more potent EGFR-TKI for EGFR-mutated NCLC patients. We showed that second-line therapy in osimertinib-resistant tumors reverted the resistance to EGFR-TKI, obtaining a PR in all mice and, after this initial response, PD in 10 of 60 mice. The median duration of first-line therapy with osimertinib plus secondline therapy with combinations until PD was approximately 28 weeks. In addition, by testing the two combination startegies in first-line therapy in the same models, we demonstarted that the addition of cetuximab or selumetinib to the EGFR-TKI osimertinib is able to increase the RR; considering all groups of mice treated with combinations, only 7 of 60 mice showed PD to first-line therapy (3 of H1975-, 2 HCC827-, and 2 PC9T790M-xenografts, respectively). Moreover, mPFS was not reached in all combination arms showing that combination treatments are superior to single agent osimertinib in terms of mPFS (p < 0.005). Interestingly, all mice reporting a clinical CR or PR maintained these response for the duration of experiment (fixed to 52 weeks) in the absence of relevant toxicities. These results confirmed that in strictly EGFRdependent models, such as our experimental model derived from three NCLC cell lines, the addition of cetuximab or selumetinib potentiated the efficacy of osimertinib in terms of clinical RR in both first-and second-line settings, and obtained a statistically significant improvement in terms of PFS when used in first-line therapy (Fig. 5) .
NGS analysis of resistant tumors confirmed that EGFR-TKI treatment exerted a selective pressure by killing EGFR-mutated cells without any new mutation detected. Our group has previously shown that the hedgehog pathway can be activated in gefitinib-resistant models, showing the cooperation between the amplified SMO protein and the overactivated MET receptor, 15 and in in vivo models of acquired resistance to sequential use of first-, second-, and third-generation EGFR-TKIs through the induction of mesenchymal properties in EGFRmutated NCLC (16) , correlating with tumor development, invasiveness, and treatment resistance. 15, 16 Thus, we investigated the activation of the hedeghog pathway in osimertinib-plus-selumetinib-resistant models through the Gli-luciferase assay and we found an upregulated Glipromoter activity and higher Gli1, SMO, and p-MAPK protein levels in two cell lines established from osimertinib-plus-selumetinib-resistant tumors (H1975 8* and PC9T790M 2*). Moreover, the sensitivity in vitro on proliferation and metastatic properties of resistant cells to treatments with sonidegib or vismodegib (this latter drug is available for clinical use for patients with skin basalioma tumors) plus selumetinib plus osimertinib confirmed that the activation of hedgehog plays a role in this model of resistance, together with EGFR-MAPK cascade signaling. Interestingly, a cooperation between hedgehog and RAS cascades has been shown in various tumor types with different mechanisms of interplay. [31] [32] [33] [34] [35] [36] In pancreatic ductal adenocarcinoma cells and in gastric cancer cells, RAS stimulates Gli transcriptional activity, inducing the expression of hedgehog target genes, using MAPK as a downstream mediator 31, 32 and, also, in gastric cancer cells, autocrine sonic hedgehog ligand (SHH) itself produces ERK1/2 activation. 33 In hepatocellular carcinoma, Gli reinforces ERK1/2-dependent invasiveness through MMP9 34 , and in melanoma cells the combination of sonidegib and BRAF-inhibitor vemurafenib synergistically affects proliferation. 35 We speculate that in EGFR-resistant NCLC, the escape to EGFR blockade through downstream MAPK signaling activation is possible through the activation of collateral pathways, including hedgehog, by the final MAPK effectors themselves, as represented schematically in Supplemental Figure 3 . 36 Collectively, these results underline the importance of studying molecular alterations during cancer progression and suggested that in EGFR-mutated NCLC a stronger inhibition of EGFR by a dual vertical blockade with combined treatment of the most potent EGFR-TKI osimertinib plus cetuximab or selumetinib represent an effective and safe novel therapeutic option. Considering the failure of the combination of afatinib plus cetuximab in the same clinical scenario, mostly due to an unacceptable toxicity profile, our results have a great translational relevance because they may lead to future clinical investigation as use of osimertinib, sparing EGFR wild-type receptor, can avoid high toxicity rates in such combinations.
Moreover, future studies of combinational strategies, including a new generation of EGFR-TKIs and inhibitors of other pathways (hedgehog), could clarify the best sequence of use of these inhibitors and identify novel predictive biomarkers for a more tailored therapy.
